Expand ACET Menu
ACET MENU

ACET Latest Press Releases

-- April 22, 2024 --

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Business Wire 4:30 PM

-- April 8, 2024 --

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference Business Wire 7:00 AM

-- March 28, 2024 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:19 PM

-- March 19, 2024 --

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Business Wire 4:10 PM

-- March 11, 2024 --

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Business Wire 7:00 AM

-- February 29, 2024 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:46 PM

-- February 5, 2024 --

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Business Wire 4:01 PM

-- January 31, 2024 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:39 PM

-- January 25, 2024 --

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares Business Wire 4:01 PM

-- January 22, 2024 --

Adicet Bio, Inc. Announces Pricing of Public Offering Business Wire 11:43 PM
Adicet Bio, Inc. Announces Proposed Public Offering Business Wire 4:28 PM

-- January 4, 2024 --

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 Business Wire 7:00 AM

-- January 3, 2024 --

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook Business Wire 4:01 PM

-- December 29, 2023 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:50 PM

-- December 10, 2023 --

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting Business Wire 12:00 PM

-- December 4, 2023 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Adicet Bio, Inc. (NASDAQ: ACET) PRNewswire 8:00 AM